[Impaired immunological status due to the urogenital chlamydiosis in women of reproductive age and its correction].
The aim of our research was to assess clinical-immunological properties of disease course and efficiency of complex etiotropic, enzyme-immunomodification therapy in women with urogenital chlamydiosis. Out of examined 818 women chlamydia was found in 276. The diagnoses of chlamydiosis in all women was assessed using the following methods: immuno-enzymatic, immunofluorescent and DNA-hybridization. Immune responses were studied in regard of forms and severity of the disease and its dynamics, as well as the regimens of treatments and their results. Vilkoxon-Mann-Witney non-parametric criterion U was used for statistical evaluation of the results. For measuring of identity of the various forms of treatment Spirman's coefficient r was used. Urogenital chlamydiosis is characterised by expressed misbalance of immune response of depressive character, the intensity of which depends upon the severity of genital pathology and obstetric anamnesis as well. Oral form of plaferon--LB enhances the immune-competent ability of the organism. The most expressive clinical effect was received using the combination of the antibiotic, enzymes and immuno-correction (95%).
Tabukashvili
N G
NG
D000276:Adjuvants, Immunologic; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002690:Chlamydia Infections / Q000150:complications / Q000276:immunology / Q000628:therapy; D003131:Combined Modality Therapy; D004338:Drug Combinations; D005260:Female; D052776:Female Urogenital Diseases / Q000276:immunology / Q000382:microbiology / Q000628:therapy; D006801:Humans; D006867:Hydrolases / Q000627:therapeutic use; D007124:Immunoenzyme Techniques; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology*; D007075:Immunoglobulin M / Q000097:blood / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods; D016898:Interferon-alpha / Q000097:blood / Q000276:immunology; D007371:Interferon-gamma / Q000097:blood / Q000276:immunology; D012431:Rutin / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D016898:Interferon-alpha; D012431:Rutin; C023295:Wobenzym; D007371:Interferon-gamma; D006867:Hydrolases